DiagnoCure Inc.

2050 René-Lévesque Blvd W., 6th floor
QUÉBEC (Qué) G1V 2K8
Toll free: 1.888.900.6626

Phone: 418.527.6100
Fax: 418-527-0240
Stock symbol: CUR


DiagnoCure is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc., recently launched the Previstage™ GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. The Company also has astrategic alliance with Gen-Probe for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure’s proprietary molecular marker. This test is also available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA™ PCA3 in vitro assay, and in Canada.